In previous issues of the journal, we have just read with great interest the paper by chen
entitled “Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating …

Empagliflozin (EMPA), a selective inhibitor of the sodium-glucose co-transporter 2, is
especially effective at regulating blood-sugar levels [1]. Compared to conventional optimum …

We aimed to probe the functions and possible mechanisms of empagliflozin in doxorubicin
(Dox)-caused cardiotoxicity. First, a cardiotoxicity rat model was built by continuously …

Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …

Background Empagliflozin showed efficacy in controlling glycaemia, leading to reductions in
HbA1c levels, weight loss and blood pressure, compared to standard treatment. Moreover …

Background Sodium-glucose cotransporter-2 inhibitors, such as empagliflozin, are pivotal
therapies for heart failure. However, the effect of empagliflozin on doxorubicin-related …

e23057 Background: Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-
transporter 2 (SGLT2), reduces the risk of hospitalization for heart failure or cardiovascular …

Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter
2, reduces the risk of hospitalization for heart failure or cardiovascular death, as seen in the …

Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter
2 (SGLT2), reduces the risk of hospitalization for heart failure or cardiovascular death in type …

Background Cyclophosphamide (CP) is a commonly used chemotherapeutic and
immunosuppressive alkylating agent. However, cardiac adverse effects of CP interfere with …